Androgens decrease and retinoids increase the expression of insulin-like growth factor-binding protein-3 in LNCaP prostatic adenocarcinoma cells

Molecular and Cellular Endocrinology

Volumn 155, Issue 1-2, 1999, Pages 9-18

  Goossens, Karine ^a   Esquenet, Murielle ^a   Swinnen, Johannnes V ^a   Manin, Michèle ^c   Rombauts, Wilfried ^b   Verhoeven, Guido ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Division of Biochemistry   (Belgium)

^c CNRS   (France)

Author keywords

Nuclear receptors; Paracrine control; Prostate cancer; Vitamin D

Indexed keywords

ALITRETINOIN; ANDROGEN; CALCITRIOL; MESSENGER RNA; METRIBOLONE; RETINOIC ACID; RETINOID; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; HUMAN; HUMAN CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION;

ADENOCARCINOMA; CALCITRIOL; CELL DIVISION; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; METRIBOLONE; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETINOIDS; TESTOSTERONE CONGENERS; TRETINOIN; TRIIODOTHYRONINE; TUMOR CELLS, CULTURED;

EID: 0032863546     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(99)00122-7     Document Type: Article

References (37)

1. Albiston A.L., Saffery R., Herington A.C. Cloning and characterization of the promoter for the rat insulin-like growth factor-binding protein-3 gene. Endocrinology. 136(2):1995;696-704.
2. Angelloz-Nicoud P., Harel L., Binoux M. Recombinant human insulin-like growth factor (IGF) binding protein-3 stimulates prostate carcinoma cell proliferation via an IGF-dependent mechanism. Role of serine proteases. Growth Regul. 6:1996;130-136.
3. Boudon C., Rodier G., Lechevallier E., Mottet N., Barenton B., Sultan Ch. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. J. Clin. Endocrinol. Metab. 81(2):1996;612-617.
4. Conover C.A., Perry J.E., Tindall D.J. Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J. Clin. Endocrinol. Metab. 80(3):1995;987-993.
5. Cubbage M.L., Suwanichkul A., Powell D.R. Insulin-like growth factor binding protein-3. Organization of the human chromosomal gene and demonstration of promoter activity. J. Biol. Chem. 265(21):1990;12642-12649.
6. Cunha G.E., Donjacour A.A., Cooke P.S., Mee S., Bigsby R.M., Higgings S.J., Sugimura Y. The endocrinology and developmental biology of the prostate. Endocr. Rev. 8:1987;338-362.
7. Dahiya R., Park H.D., Cusick J., Vessella R.L., Fournier G., Narayan P. Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int. J. Cancer. 59:1994;126-132.
8. Esquenet M., Swinnen J.V., Heyns W., Verhoeven G. Triiodothyronine modulates growth, secretory function and androgen receptor concentration in the prostatic carcinoma cell line LNCaP. Mol. Cell. Endocrinol. 109:1995;105-111.
9. Esquenet M., Swinnen J.V., Heyns W., Verhoeven G. The control of LNCaP cell proliferation and differentiation: actions and interactions of androgens, 1α,25-dihydroxycholecalciferol, all-trans-retinoic acid, 9-cis-retinoic acid and phenylacetate. Prostate. 28:1996;182-194.
10. Esquenet M., Swinnen J.V., Heyns W., Verhoeven G. LNCaP prostatic adenocarinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids. J. Steroid Biochem. Molec. Biol. 62:1997;391-399.
11. Fong C.J., Sutkowski D.M., Braun E.J., Bauer K.D., Sherwood E.R., Lee C., Kozlowski J.M. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. J. Urol. 49:1993;1190-1194.
12. Garnick M.B. Prostate cancer: screening, diagnosis, and management. Ann. Intern. Med. 118:1993;804-818.
13. Gucev Z.S., Oh Y., Kelley K.M., Rosenfeld R.G. Insulin-like growth factor binding protein-3 mediates retinoic acid- and transforming growth factor β2-induced growth inhibition in human breast cancer cells. Cancer Res. 56:1996;1545-1550.
14. Hanchette C.L., Schwartz G.G. Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer. 70:1992;2861-2869.
15. Hwa V., Oh Y., Rosenfeld R.G. Insulin-like growth factor binding protein-3 and -5 are regulated by transforming growth factor-β and retinoic acid in the human prostate adenocarinoma cell line PC-3. Endocrine. 6(3):1997;235-242.
16. Iwamura M., Sluss P.M., Casamento J.B., Cockett A.T.K. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate. 22:1993;243-252.
17. Jaques G., Noll K., Wegmann B., Witten S., Kogan E., Radulescu R.T., Havemann K. Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology. 138(4):1997;1767-1770.
18. Kanety H., Madjar Y., Dagan Y., Levi J., Papa M.Z., Pariente C., Goldwasser B., Karasik A. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J. Clin. Endocrinol. Metab. 77(1):1993;229-233.
19. Kimura G., Kasuya J., Giannini S., Honda Y., Mohan S., Kawachi M., Akimoto M., Fujita-Yamaguchi Y. Insulin-like growth factor (IGF) system components in human prostatic cancer cell lines: LNCaP, DU-145, and PC-3 cells. Int. J. Urol. 3(1):1996;39-46.
20. Kokontis J., Takakura K., Hay N., Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 54:1994;1566-1573.
21. Labarca C., Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem. 102:1980;344-352.
22. Leake R.E., Freshney R.I., Munir I. Steroid response in vivo and in vitro. Green B., Leake R.E. Steroid Hormones: A Practical Approach. 1987;214 IRL Press, Washington, DC.
23. Long R.J., Roberts K.P., Wilson M.J., Ercole C.J., Pryor J.L. Prostate cancer: a clinical and basic science review. J. Andrology. 18(1):1997;15-20.
24. Marcelli M., Haidacher S.J., Plymate S.R., Birnbaum R.S. Altered growth and insulin-like growth factor-binding protein-3 production in PC3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology. 136(3):1995;1040-1048.
25. Martin J.L., Coverley J.A., Pattison S.T., Baxter R.C. Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology. 136(3):1995;1219-1226.
26. Pietrzkowski Z., Mulholland G., Gomella L., Jameson B.A., Wernicke D., Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. 53:1993;1102-1106.
27. Plymate S.R., Tennant M., Birnbaum R.S., Thrasher J.B., Chatta G., Ware J.L. The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. J. Clin. Endocrinol. Metab. 81(10):1996;3709-3716.
28. Rajah R., Valentinis B., Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem. 272(18):1997;12181-12188.
29. Shimasaki S., Ling N. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog. Growth Factor Res. 3(4):1991;243-266.
30. 3 receptors and actions in human prostate cancer cell lines. Endocrinology. 132:1993;1952-1960.
31. Swinnen J.V., Esquenet M., Heyns W., Rombauts W., Verhoeven G. Androgen regulation of the messenger RNA encoding diazepam-binding inhibitor/acyl-CoA-binding protein in the human prostatic adenocorcinoma cell line LNCaP. Mol. Cell. Endocrinol. 104:1994;153-162.
32. Tennant M.K., Thrasher J.B., Twomey P.A., Birnbaum R.S., Plymate S.R. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J. Clin. Endocrinol. Metab. 81(1):1996;411-420.
33. Tennant M.K., Thrasher J.B., Twomey P.A., Birnbaum R.S., Plymate S.R. Insulin-like growth factor-binding proteins (IGFBP) -4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization. J. Clin. Endocrinol. Metab. 81(10):1996;3783-3792.
34. Verhoeven G., Deboel L., Swinnen J., Rombauts L., Vanderhoydonck F., Rosseels J., Hoeben E., Heyns W. Effect of androgens on the germ-cell depleted testes of prenatally irradiated rats. Int. J. Androl. 18:1995;23-34.
35. Wolf D.A., Kohlhuber F., Schulz P., Fittler F., Eick D. Transcriptional down-regulation of c-myc in human prostate carcinoma cells by the synthetic androgen mibolerone. Br. J. Cancer. 65:1992;376-382.
36. Young C.Y.F., Murtha P.E., Andrews P.E., Lindzey J.K., Tindall D.J. Antagonism of androgen action in prostate tumor cells by retinoic acid. Prostate. 25:1994;39-45.
37. Zadeh S.M., Binoux M. The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene. Endocrinology. 138(7):1997;3069-3072.